nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—POU4F1—glaucoma	0.000937	0.0585	CbGpPWpGaD
Naltrexone—ABCB1—ABC-family proteins mediated transport—PEX19—glaucoma	0.000726	0.0453	CbGpPWpGaD
Naltrexone—UGT1A1—Estrogen metabolism—CYP1B1—glaucoma	0.00063	0.0393	CbGpPWpGaD
Naltrexone—Depression—Timolol—glaucoma	0.000582	0.000591	CcSEcCtD
Naltrexone—Angiopathy—Betaxolol—glaucoma	0.000582	0.000591	CcSEcCtD
Naltrexone—Pruritus—Bimatoprost—glaucoma	0.00058	0.00059	CcSEcCtD
Naltrexone—Immune system disorder—Betaxolol—glaucoma	0.000579	0.000589	CcSEcCtD
Naltrexone—Diarrhoea—Apraclonidine—glaucoma	0.000579	0.000588	CcSEcCtD
Naltrexone—Malaise—Clonidine—glaucoma	0.000578	0.000588	CcSEcCtD
Naltrexone—Mediastinal disorder—Betaxolol—glaucoma	0.000578	0.000587	CcSEcCtD
Naltrexone—Chills—Betaxolol—glaucoma	0.000575	0.000585	CcSEcCtD
Naltrexone—Syncope—Clonidine—glaucoma	0.000575	0.000584	CcSEcCtD
Naltrexone—Feeling abnormal—Dorzolamide—glaucoma	0.000571	0.000581	CcSEcCtD
Naltrexone—Decreased appetite—Pilocarpine—glaucoma	0.00057	0.000579	CcSEcCtD
Naltrexone—Feeling abnormal—Travoprost—glaucoma	0.000569	0.000578	CcSEcCtD
Naltrexone—Conjunctivitis—Timolol—glaucoma	0.000567	0.000576	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dorzolamide—glaucoma	0.000567	0.000576	CcSEcCtD
Naltrexone—Alopecia—Betaxolol—glaucoma	0.000567	0.000576	CcSEcCtD
Naltrexone—Palpitations—Clonidine—glaucoma	0.000567	0.000576	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000566	0.000575	CcSEcCtD
Naltrexone—Gastrointestinal pain—Travoprost—glaucoma	0.000565	0.000574	CcSEcCtD
Naltrexone—Loss of consciousness—Clonidine—glaucoma	0.000563	0.000573	CcSEcCtD
Naltrexone—Feeling abnormal—Brinzolamide—glaucoma	0.000562	0.000571	CcSEcCtD
Naltrexone—Mental disorder—Betaxolol—glaucoma	0.000562	0.000571	CcSEcCtD
Naltrexone—Constipation—Pilocarpine—glaucoma	0.00056	0.000569	CcSEcCtD
Naltrexone—Pain—Pilocarpine—glaucoma	0.00056	0.000569	CcSEcCtD
Naltrexone—Cough—Clonidine—glaucoma	0.000559	0.000569	CcSEcCtD
Naltrexone—Dizziness—Apraclonidine—glaucoma	0.000559	0.000568	CcSEcCtD
Naltrexone—Malnutrition—Betaxolol—glaucoma	0.000558	0.000567	CcSEcCtD
Naltrexone—Urticaria—Dorzolamide—glaucoma	0.000551	0.00056	CcSEcCtD
Naltrexone—Epistaxis—Timolol—glaucoma	0.00055	0.000559	CcSEcCtD
Naltrexone—Abdominal pain—Dorzolamide—glaucoma	0.000548	0.000557	CcSEcCtD
Naltrexone—Body temperature increased—Dorzolamide—glaucoma	0.000548	0.000557	CcSEcCtD
Naltrexone—Tension—Betaxolol—glaucoma	0.000548	0.000557	CcSEcCtD
Naltrexone—Sinusitis—Timolol—glaucoma	0.000547	0.000556	CcSEcCtD
Naltrexone—Dysgeusia—Betaxolol—glaucoma	0.000547	0.000555	CcSEcCtD
Naltrexone—Chest pain—Clonidine—glaucoma	0.000546	0.000555	CcSEcCtD
Naltrexone—Arthralgia—Clonidine—glaucoma	0.000546	0.000555	CcSEcCtD
Naltrexone—Abdominal pain—Travoprost—glaucoma	0.000546	0.000555	CcSEcCtD
Naltrexone—Anxiety—Clonidine—glaucoma	0.000544	0.000553	CcSEcCtD
Naltrexone—Asthenia—Acetazolamide—glaucoma	0.000543	0.000552	CcSEcCtD
Naltrexone—Dizziness—Bimatoprost—glaucoma	0.000542	0.000551	CcSEcCtD
Naltrexone—Nervousness—Betaxolol—glaucoma	0.000542	0.000551	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000542	0.000551	CcSEcCtD
Naltrexone—Urticaria—Brinzolamide—glaucoma	0.000542	0.00055	CcSEcCtD
Naltrexone—Feeling abnormal—Pilocarpine—glaucoma	0.00054	0.000549	CcSEcCtD
Naltrexone—Discomfort—Clonidine—glaucoma	0.000539	0.000548	CcSEcCtD
Naltrexone—Vomiting—Apraclonidine—glaucoma	0.000538	0.000546	CcSEcCtD
Naltrexone—Muscle spasms—Betaxolol—glaucoma	0.000537	0.000545	CcSEcCtD
Naltrexone—Gastrointestinal pain—Pilocarpine—glaucoma	0.000536	0.000545	CcSEcCtD
Naltrexone—Hypersensitivity—Brimonidine—glaucoma	0.000535	0.000544	CcSEcCtD
Naltrexone—Dry mouth—Clonidine—glaucoma	0.000534	0.000543	CcSEcCtD
Naltrexone—Dermatitis—Apraclonidine—glaucoma	0.000533	0.000541	CcSEcCtD
Naltrexone—Headache—Apraclonidine—glaucoma	0.00053	0.000538	CcSEcCtD
Naltrexone—Confusional state—Clonidine—glaucoma	0.000528	0.000536	CcSEcCtD
Naltrexone—Vision blurred—Betaxolol—glaucoma	0.000526	0.000535	CcSEcCtD
Naltrexone—Oedema—Clonidine—glaucoma	0.000523	0.000532	CcSEcCtD
Naltrexone—Tremor—Betaxolol—glaucoma	0.000523	0.000531	CcSEcCtD
Naltrexone—Hallucination—Timolol—glaucoma	0.000521	0.00053	CcSEcCtD
Naltrexone—Asthenia—Brimonidine—glaucoma	0.000521	0.000529	CcSEcCtD
Naltrexone—Infection—Clonidine—glaucoma	0.00052	0.000528	CcSEcCtD
Naltrexone—Body temperature increased—Pilocarpine—glaucoma	0.000518	0.000526	CcSEcCtD
Naltrexone—Abdominal pain—Pilocarpine—glaucoma	0.000518	0.000526	CcSEcCtD
Naltrexone—Ill-defined disorder—Betaxolol—glaucoma	0.000518	0.000526	CcSEcCtD
Naltrexone—Diarrhoea—Acetazolamide—glaucoma	0.000518	0.000526	CcSEcCtD
Naltrexone—Rash—Bimatoprost—glaucoma	0.000517	0.000525	CcSEcCtD
Naltrexone—Dermatitis—Bimatoprost—glaucoma	0.000517	0.000525	CcSEcCtD
Naltrexone—Shock—Clonidine—glaucoma	0.000515	0.000523	CcSEcCtD
Naltrexone—Connective tissue disorder—Timolol—glaucoma	0.000515	0.000523	CcSEcCtD
Naltrexone—Pruritus—Brimonidine—glaucoma	0.000514	0.000522	CcSEcCtD
Naltrexone—Headache—Bimatoprost—glaucoma	0.000514	0.000522	CcSEcCtD
Naltrexone—Nervous system disorder—Clonidine—glaucoma	0.000513	0.000521	CcSEcCtD
Naltrexone—Hypersensitivity—Dorzolamide—glaucoma	0.000511	0.000519	CcSEcCtD
Naltrexone—Tachycardia—Clonidine—glaucoma	0.000511	0.000519	CcSEcCtD
Naltrexone—Hypersensitivity—Travoprost—glaucoma	0.000509	0.000517	CcSEcCtD
Naltrexone—Skin disorder—Clonidine—glaucoma	0.000508	0.000517	CcSEcCtD
Naltrexone—Hyperhidrosis—Clonidine—glaucoma	0.000506	0.000514	CcSEcCtD
Naltrexone—UGT1A1—Estrogen metabolism—GSTM1—glaucoma	0.000503	0.0314	CbGpPWpGaD
Naltrexone—Malaise—Betaxolol—glaucoma	0.000503	0.000512	CcSEcCtD
Naltrexone—Nausea—Apraclonidine—glaucoma	0.000502	0.000511	CcSEcCtD
Naltrexone—Hypersensitivity—Brinzolamide—glaucoma	0.000502	0.00051	CcSEcCtD
Naltrexone—Syncope—Betaxolol—glaucoma	0.000501	0.000509	CcSEcCtD
Naltrexone—Dizziness—Acetazolamide—glaucoma	0.0005	0.000508	CcSEcCtD
Naltrexone—Anorexia—Clonidine—glaucoma	0.000499	0.000507	CcSEcCtD
Naltrexone—Asthenia—Dorzolamide—glaucoma	0.000498	0.000506	CcSEcCtD
Naltrexone—Asthenia—Travoprost—glaucoma	0.000495	0.000503	CcSEcCtD
Naltrexone—Palpitations—Betaxolol—glaucoma	0.000493	0.000501	CcSEcCtD
Naltrexone—Pruritus—Dorzolamide—glaucoma	0.000491	0.000499	CcSEcCtD
Naltrexone—Loss of consciousness—Betaxolol—glaucoma	0.000491	0.000499	CcSEcCtD
Naltrexone—Eye disorder—Timolol—glaucoma	0.00049	0.000497	CcSEcCtD
Naltrexone—Asthenia—Brinzolamide—glaucoma	0.000489	0.000497	CcSEcCtD
Naltrexone—Pruritus—Travoprost—glaucoma	0.000488	0.000496	CcSEcCtD
Naltrexone—Tinnitus—Timolol—glaucoma	0.000488	0.000496	CcSEcCtD
Naltrexone—Cough—Betaxolol—glaucoma	0.000487	0.000495	CcSEcCtD
Naltrexone—Nausea—Bimatoprost—glaucoma	0.000487	0.000495	CcSEcCtD
Naltrexone—Cardiac disorder—Timolol—glaucoma	0.000486	0.000494	CcSEcCtD
Naltrexone—Hypersensitivity—Pilocarpine—glaucoma	0.000483	0.000491	CcSEcCtD
Naltrexone—Pruritus—Brinzolamide—glaucoma	0.000482	0.00049	CcSEcCtD
Naltrexone—Vomiting—Acetazolamide—glaucoma	0.000481	0.000489	CcSEcCtD
Naltrexone—Dizziness—Brimonidine—glaucoma	0.00048	0.000488	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Clonidine—glaucoma	0.000477	0.000484	CcSEcCtD
Naltrexone—Angiopathy—Timolol—glaucoma	0.000475	0.000483	CcSEcCtD
Naltrexone—Arthralgia—Betaxolol—glaucoma	0.000475	0.000483	CcSEcCtD
Naltrexone—Chest pain—Betaxolol—glaucoma	0.000475	0.000483	CcSEcCtD
Naltrexone—Myalgia—Betaxolol—glaucoma	0.000475	0.000483	CcSEcCtD
Naltrexone—Diarrhoea—Dorzolamide—glaucoma	0.000474	0.000482	CcSEcCtD
Naltrexone—Headache—Acetazolamide—glaucoma	0.000474	0.000482	CcSEcCtD
Naltrexone—Anxiety—Betaxolol—glaucoma	0.000474	0.000481	CcSEcCtD
Naltrexone—Insomnia—Clonidine—glaucoma	0.000473	0.000481	CcSEcCtD
Naltrexone—Immune system disorder—Timolol—glaucoma	0.000473	0.000481	CcSEcCtD
Naltrexone—Diarrhoea—Travoprost—glaucoma	0.000472	0.00048	CcSEcCtD
Naltrexone—Mediastinal disorder—Timolol—glaucoma	0.000472	0.00048	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000472	0.00048	CcSEcCtD
Naltrexone—Asthenia—Pilocarpine—glaucoma	0.00047	0.000478	CcSEcCtD
Naltrexone—Paraesthesia—Clonidine—glaucoma	0.00047	0.000477	CcSEcCtD
Naltrexone—Discomfort—Betaxolol—glaucoma	0.00047	0.000477	CcSEcCtD
Naltrexone—Dyspnoea—Clonidine—glaucoma	0.000466	0.000474	CcSEcCtD
Naltrexone—Diarrhoea—Brinzolamide—glaucoma	0.000466	0.000474	CcSEcCtD
Naltrexone—Somnolence—Clonidine—glaucoma	0.000465	0.000473	CcSEcCtD
Naltrexone—Dry mouth—Betaxolol—glaucoma	0.000465	0.000472	CcSEcCtD
Naltrexone—Pruritus—Pilocarpine—glaucoma	0.000464	0.000471	CcSEcCtD
Naltrexone—Alopecia—Timolol—glaucoma	0.000463	0.00047	CcSEcCtD
Naltrexone—Confusional state—Betaxolol—glaucoma	0.000459	0.000467	CcSEcCtD
Naltrexone—Mental disorder—Timolol—glaucoma	0.000459	0.000466	CcSEcCtD
Naltrexone—Dizziness—Dorzolamide—glaucoma	0.000459	0.000466	CcSEcCtD
Naltrexone—Rash—Brimonidine—glaucoma	0.000458	0.000465	CcSEcCtD
Naltrexone—Dermatitis—Brimonidine—glaucoma	0.000457	0.000465	CcSEcCtD
Naltrexone—Dizziness—Travoprost—glaucoma	0.000457	0.000464	CcSEcCtD
Naltrexone—Malnutrition—Timolol—glaucoma	0.000456	0.000463	CcSEcCtD
Naltrexone—Oedema—Betaxolol—glaucoma	0.000456	0.000463	CcSEcCtD
Naltrexone—Headache—Brimonidine—glaucoma	0.000455	0.000462	CcSEcCtD
Naltrexone—Decreased appetite—Clonidine—glaucoma	0.000455	0.000462	CcSEcCtD
Naltrexone—Infection—Betaxolol—glaucoma	0.000453	0.00046	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Clonidine—glaucoma	0.000452	0.000459	CcSEcCtD
Naltrexone—Fatigue—Clonidine—glaucoma	0.000451	0.000458	CcSEcCtD
Naltrexone—Dizziness—Brinzolamide—glaucoma	0.000451	0.000458	CcSEcCtD
Naltrexone—Nausea—Acetazolamide—glaucoma	0.000449	0.000457	CcSEcCtD
Naltrexone—Diarrhoea—Pilocarpine—glaucoma	0.000448	0.000456	CcSEcCtD
Naltrexone—Shock—Betaxolol—glaucoma	0.000448	0.000455	CcSEcCtD
Naltrexone—Tension—Timolol—glaucoma	0.000447	0.000455	CcSEcCtD
Naltrexone—Pain—Clonidine—glaucoma	0.000447	0.000455	CcSEcCtD
Naltrexone—Constipation—Clonidine—glaucoma	0.000447	0.000455	CcSEcCtD
Naltrexone—Nervous system disorder—Betaxolol—glaucoma	0.000447	0.000454	CcSEcCtD
Naltrexone—Dysgeusia—Timolol—glaucoma	0.000447	0.000454	CcSEcCtD
Naltrexone—Tachycardia—Betaxolol—glaucoma	0.000445	0.000452	CcSEcCtD
Naltrexone—Nervousness—Timolol—glaucoma	0.000443	0.00045	CcSEcCtD
Naltrexone—Skin disorder—Betaxolol—glaucoma	0.000442	0.00045	CcSEcCtD
Naltrexone—Vomiting—Dorzolamide—glaucoma	0.000441	0.000448	CcSEcCtD
Naltrexone—Hyperhidrosis—Betaxolol—glaucoma	0.00044	0.000448	CcSEcCtD
Naltrexone—Rash—Dorzolamide—glaucoma	0.000437	0.000444	CcSEcCtD
Naltrexone—Dermatitis—Dorzolamide—glaucoma	0.000437	0.000444	CcSEcCtD
Naltrexone—Rash—Travoprost—glaucoma	0.000435	0.000442	CcSEcCtD
Naltrexone—Dermatitis—Travoprost—glaucoma	0.000435	0.000442	CcSEcCtD
Naltrexone—Headache—Dorzolamide—glaucoma	0.000434	0.000441	CcSEcCtD
Naltrexone—Anorexia—Betaxolol—glaucoma	0.000434	0.000441	CcSEcCtD
Naltrexone—Vomiting—Brinzolamide—glaucoma	0.000433	0.000441	CcSEcCtD
Naltrexone—Dizziness—Pilocarpine—glaucoma	0.000433	0.00044	CcSEcCtD
Naltrexone—Headache—Travoprost—glaucoma	0.000433	0.00044	CcSEcCtD
Naltrexone—Nausea—Brimonidine—glaucoma	0.000431	0.000438	CcSEcCtD
Naltrexone—Feeling abnormal—Clonidine—glaucoma	0.000431	0.000438	CcSEcCtD
Naltrexone—Rash—Brinzolamide—glaucoma	0.00043	0.000437	CcSEcCtD
Naltrexone—Vision blurred—Timolol—glaucoma	0.00043	0.000437	CcSEcCtD
Naltrexone—Dermatitis—Brinzolamide—glaucoma	0.000429	0.000436	CcSEcCtD
Naltrexone—Gastrointestinal pain—Clonidine—glaucoma	0.000428	0.000435	CcSEcCtD
Naltrexone—Headache—Brinzolamide—glaucoma	0.000427	0.000434	CcSEcCtD
Naltrexone—Angioedema—Timolol—glaucoma	0.000417	0.000423	CcSEcCtD
Naltrexone—Vomiting—Pilocarpine—glaucoma	0.000417	0.000423	CcSEcCtD
Naltrexone—Urticaria—Clonidine—glaucoma	0.000416	0.000422	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000415	0.000422	CcSEcCtD
Naltrexone—Abdominal pain—Clonidine—glaucoma	0.000414	0.00042	CcSEcCtD
Naltrexone—Body temperature increased—Clonidine—glaucoma	0.000414	0.00042	CcSEcCtD
Naltrexone—Rash—Pilocarpine—glaucoma	0.000413	0.00042	CcSEcCtD
Naltrexone—Dermatitis—Pilocarpine—glaucoma	0.000413	0.000419	CcSEcCtD
Naltrexone—Insomnia—Betaxolol—glaucoma	0.000412	0.000419	CcSEcCtD
Naltrexone—Nausea—Dorzolamide—glaucoma	0.000412	0.000419	CcSEcCtD
Naltrexone—Headache—Pilocarpine—glaucoma	0.00041	0.000417	CcSEcCtD
Naltrexone—Nausea—Travoprost—glaucoma	0.00041	0.000417	CcSEcCtD
Naltrexone—Paraesthesia—Betaxolol—glaucoma	0.000409	0.000416	CcSEcCtD
Naltrexone—Syncope—Timolol—glaucoma	0.000409	0.000416	CcSEcCtD
Naltrexone—Dyspnoea—Betaxolol—glaucoma	0.000406	0.000413	CcSEcCtD
Naltrexone—Nausea—Brinzolamide—glaucoma	0.000405	0.000412	CcSEcCtD
Naltrexone—Palpitations—Timolol—glaucoma	0.000403	0.00041	CcSEcCtD
Naltrexone—Loss of consciousness—Timolol—glaucoma	0.000401	0.000407	CcSEcCtD
Naltrexone—Cough—Timolol—glaucoma	0.000398	0.000404	CcSEcCtD
Naltrexone—Decreased appetite—Betaxolol—glaucoma	0.000396	0.000402	CcSEcCtD
Naltrexone—Hypertension—Timolol—glaucoma	0.000394	0.0004	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Betaxolol—glaucoma	0.000393	0.0004	CcSEcCtD
Naltrexone—Fatigue—Betaxolol—glaucoma	0.000393	0.000399	CcSEcCtD
Naltrexone—Pain—Betaxolol—glaucoma	0.00039	0.000396	CcSEcCtD
Naltrexone—Constipation—Betaxolol—glaucoma	0.00039	0.000396	CcSEcCtD
Naltrexone—Nausea—Pilocarpine—glaucoma	0.000389	0.000396	CcSEcCtD
Naltrexone—Chest pain—Timolol—glaucoma	0.000388	0.000395	CcSEcCtD
Naltrexone—Arthralgia—Timolol—glaucoma	0.000388	0.000395	CcSEcCtD
Naltrexone—Myalgia—Timolol—glaucoma	0.000388	0.000395	CcSEcCtD
Naltrexone—Anxiety—Timolol—glaucoma	0.000387	0.000393	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000386	0.000392	CcSEcCtD
Naltrexone—Hypersensitivity—Clonidine—glaucoma	0.000386	0.000392	CcSEcCtD
Naltrexone—Discomfort—Timolol—glaucoma	0.000384	0.00039	CcSEcCtD
Naltrexone—Dry mouth—Timolol—glaucoma	0.00038	0.000386	CcSEcCtD
Naltrexone—Asthenia—Clonidine—glaucoma	0.000375	0.000382	CcSEcCtD
Naltrexone—Feeling abnormal—Betaxolol—glaucoma	0.000375	0.000382	CcSEcCtD
Naltrexone—Confusional state—Timolol—glaucoma	0.000375	0.000381	CcSEcCtD
Naltrexone—Anaphylactic shock—Timolol—glaucoma	0.000372	0.000378	CcSEcCtD
Naltrexone—Oedema—Timolol—glaucoma	0.000372	0.000378	CcSEcCtD
Naltrexone—Pruritus—Clonidine—glaucoma	0.00037	0.000376	CcSEcCtD
Naltrexone—Infection—Timolol—glaucoma	0.00037	0.000376	CcSEcCtD
Naltrexone—Shock—Timolol—glaucoma	0.000366	0.000372	CcSEcCtD
Naltrexone—Nervous system disorder—Timolol—glaucoma	0.000365	0.000371	CcSEcCtD
Naltrexone—Urticaria—Betaxolol—glaucoma	0.000362	0.000368	CcSEcCtD
Naltrexone—Skin disorder—Timolol—glaucoma	0.000361	0.000367	CcSEcCtD
Naltrexone—Body temperature increased—Betaxolol—glaucoma	0.00036	0.000366	CcSEcCtD
Naltrexone—Hyperhidrosis—Timolol—glaucoma	0.00036	0.000366	CcSEcCtD
Naltrexone—Diarrhoea—Clonidine—glaucoma	0.000358	0.000364	CcSEcCtD
Naltrexone—Anorexia—Timolol—glaucoma	0.000355	0.000361	CcSEcCtD
Naltrexone—Dizziness—Clonidine—glaucoma	0.000346	0.000352	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Timolol—glaucoma	0.000339	0.000345	CcSEcCtD
Naltrexone—Insomnia—Timolol—glaucoma	0.000337	0.000342	CcSEcCtD
Naltrexone—Hypersensitivity—Betaxolol—glaucoma	0.000336	0.000341	CcSEcCtD
Naltrexone—Paraesthesia—Timolol—glaucoma	0.000334	0.00034	CcSEcCtD
Naltrexone—Vomiting—Clonidine—glaucoma	0.000333	0.000338	CcSEcCtD
Naltrexone—Dyspnoea—Timolol—glaucoma	0.000332	0.000337	CcSEcCtD
Naltrexone—Somnolence—Timolol—glaucoma	0.000331	0.000336	CcSEcCtD
Naltrexone—Rash—Clonidine—glaucoma	0.00033	0.000335	CcSEcCtD
Naltrexone—Dermatitis—Clonidine—glaucoma	0.00033	0.000335	CcSEcCtD
Naltrexone—Headache—Clonidine—glaucoma	0.000328	0.000333	CcSEcCtD
Naltrexone—Asthenia—Betaxolol—glaucoma	0.000327	0.000332	CcSEcCtD
Naltrexone—Decreased appetite—Timolol—glaucoma	0.000324	0.000329	CcSEcCtD
Naltrexone—Pruritus—Betaxolol—glaucoma	0.000322	0.000328	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Timolol—glaucoma	0.000321	0.000327	CcSEcCtD
Naltrexone—Fatigue—Timolol—glaucoma	0.000321	0.000326	CcSEcCtD
Naltrexone—Pain—Timolol—glaucoma	0.000318	0.000323	CcSEcCtD
Naltrexone—Diarrhoea—Betaxolol—glaucoma	0.000312	0.000317	CcSEcCtD
Naltrexone—Nausea—Clonidine—glaucoma	0.000311	0.000316	CcSEcCtD
Naltrexone—Feeling abnormal—Timolol—glaucoma	0.000307	0.000312	CcSEcCtD
Naltrexone—Gastrointestinal pain—Timolol—glaucoma	0.000304	0.000309	CcSEcCtD
Naltrexone—Dizziness—Betaxolol—glaucoma	0.000301	0.000306	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—glaucoma	0.000297	0.0186	CbGpPWpGaD
Naltrexone—Urticaria—Timolol—glaucoma	0.000296	0.0003	CcSEcCtD
Naltrexone—Body temperature increased—Timolol—glaucoma	0.000294	0.000299	CcSEcCtD
Naltrexone—Abdominal pain—Timolol—glaucoma	0.000294	0.000299	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000292	0.0182	CbGpPWpGaD
Naltrexone—Vomiting—Betaxolol—glaucoma	0.00029	0.000294	CcSEcCtD
Naltrexone—Rash—Betaxolol—glaucoma	0.000287	0.000292	CcSEcCtD
Naltrexone—Dermatitis—Betaxolol—glaucoma	0.000287	0.000292	CcSEcCtD
Naltrexone—Headache—Betaxolol—glaucoma	0.000285	0.00029	CcSEcCtD
Naltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—BDNF—glaucoma	0.000278	0.0174	CbGpPWpGaD
Naltrexone—Hypersensitivity—Timolol—glaucoma	0.000274	0.000279	CcSEcCtD
Naltrexone—Nausea—Betaxolol—glaucoma	0.000271	0.000275	CcSEcCtD
Naltrexone—Asthenia—Timolol—glaucoma	0.000267	0.000271	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000267	0.0167	CbGpPWpGaD
Naltrexone—Pruritus—Timolol—glaucoma	0.000263	0.000268	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000256	0.016	CbGpPWpGaD
Naltrexone—Diarrhoea—Timolol—glaucoma	0.000255	0.000259	CcSEcCtD
Naltrexone—Dizziness—Timolol—glaucoma	0.000246	0.00025	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.00024	0.015	CbGpPWpGaD
Naltrexone—Vomiting—Timolol—glaucoma	0.000237	0.00024	CcSEcCtD
Naltrexone—Rash—Timolol—glaucoma	0.000235	0.000238	CcSEcCtD
Naltrexone—Dermatitis—Timolol—glaucoma	0.000234	0.000238	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000234	0.0146	CbGpPWpGaD
Naltrexone—Headache—Timolol—glaucoma	0.000233	0.000237	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A13—glaucoma	0.000233	0.0145	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000229	0.0143	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTT1—glaucoma	0.000222	0.0139	CbGpPWpGaD
Naltrexone—Nausea—Timolol—glaucoma	0.000221	0.000225	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000216	0.0135	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000211	0.0131	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000206	0.0128	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.0002	0.0125	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000198	0.0123	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TXN—glaucoma	0.000191	0.0119	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000191	0.0119	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.00018	0.0113	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000178	0.0111	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—OPN4—glaucoma	0.000174	0.0109	CbGpPWpGaD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000174	0.0108	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—SLC6A1—glaucoma	0.00017	0.0106	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000169	0.0106	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—PTGFR—glaucoma	0.000157	0.00978	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—BCL2L1—glaucoma	0.000155	0.00967	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—OPN4—glaucoma	0.000153	0.00953	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000153	0.00952	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTM1—glaucoma	0.000141	0.00883	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFB2—glaucoma	0.000139	0.00866	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—PTGFR—glaucoma	0.000137	0.00858	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL1A—glaucoma	0.000137	0.00853	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTT1—glaucoma	0.00013	0.00811	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—OPN4—glaucoma	0.000129	0.00805	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	0.000127	0.00792	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—FAS—glaucoma	0.000122	0.0076	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—PTGFR—glaucoma	0.000116	0.00725	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—CYP1B1—glaucoma	0.000104	0.00646	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP1B1—glaucoma	0.000102	0.00637	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—EDN1—glaucoma	0.000102	0.00637	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—OPN4—glaucoma	9.84e-05	0.00614	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTM1—glaucoma	9.43e-05	0.00589	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA5A—glaucoma	9.1e-05	0.00568	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NARFL—glaucoma	9.1e-05	0.00568	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	9.05e-05	0.00565	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—EDN1—glaucoma	8.94e-05	0.00558	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—OPN4—glaucoma	8.93e-05	0.00558	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—C3—glaucoma	8.91e-05	0.00556	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PTGFR—glaucoma	8.86e-05	0.00553	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—OPN4—glaucoma	8.63e-05	0.00538	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTM1—glaucoma	8.27e-05	0.00516	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	8.26e-05	0.00516	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTM1—glaucoma	8.16e-05	0.00509	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PTGFR—glaucoma	8.04e-05	0.00502	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—SMO—glaucoma	7.9e-05	0.00493	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—OPN4—glaucoma	7.83e-05	0.00489	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—C3—glaucoma	7.81e-05	0.00488	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PTGFR—glaucoma	7.77e-05	0.00485	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LRP12—glaucoma	7.61e-05	0.00475	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	7.58e-05	0.00473	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—EDN1—glaucoma	7.56e-05	0.00472	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—C3—glaucoma	7.52e-05	0.00469	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—OPN4—glaucoma	7.29e-05	0.00455	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL1A—glaucoma	7.11e-05	0.00444	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTGFR—glaucoma	7.05e-05	0.0044	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—SMO—glaucoma	6.93e-05	0.00433	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	6.84e-05	0.00427	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LRP12—glaucoma	6.68e-05	0.00417	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—OPN4—glaucoma	6.62e-05	0.00413	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—C3—glaucoma	6.6e-05	0.00412	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—C3—glaucoma	6.59e-05	0.00411	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTGFR—glaucoma	6.56e-05	0.0041	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—FAS—glaucoma	6.34e-05	0.00396	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—C3—glaucoma	6.25e-05	0.0039	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	6e-05	0.00374	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	5.98e-05	0.00373	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTGFR—glaucoma	5.96e-05	0.00372	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—SMO—glaucoma	5.86e-05	0.00366	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LRP12—glaucoma	5.64e-05	0.00352	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—C3—glaucoma	5.57e-05	0.00348	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	5.53e-05	0.00345	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	5.36e-05	0.00334	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—OPN4—glaucoma	5.28e-05	0.00329	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	5.24e-05	0.00327	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—EDN1—glaucoma	5.21e-05	0.00325	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	5.12e-05	0.0032	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	5.07e-05	0.00316	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HEYL—glaucoma	4.91e-05	0.00306	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTGFR—glaucoma	4.75e-05	0.00297	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—OPN4—glaucoma	4.63e-05	0.00289	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—EDN1—glaucoma	4.57e-05	0.00285	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—C3—glaucoma	4.55e-05	0.00284	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA1—glaucoma	4.45e-05	0.00278	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	4.43e-05	0.00276	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CTSA—glaucoma	4.31e-05	0.00269	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HEYL—glaucoma	4.3e-05	0.00269	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA5A—glaucoma	4.18e-05	0.00261	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NARFL—glaucoma	4.18e-05	0.00261	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTGFR—glaucoma	4.17e-05	0.0026	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA2—glaucoma	4.07e-05	0.00254	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—SMO—glaucoma	4.06e-05	0.00253	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	3.99e-05	0.00249	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—C3—glaucoma	3.99e-05	0.00249	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—OPN4—glaucoma	3.91e-05	0.00244	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—EDN1—glaucoma	3.86e-05	0.00241	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RPTOR—glaucoma	3.72e-05	0.00232	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	3.68e-05	0.0023	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	3.66e-05	0.00228	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HEYL—glaucoma	3.64e-05	0.00227	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	3.63e-05	0.00226	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NCK2—glaucoma	3.6e-05	0.00225	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—SMO—glaucoma	3.56e-05	0.00222	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTGFR—glaucoma	3.52e-05	0.0022	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	3.42e-05	0.00213	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—C3—glaucoma	3.37e-05	0.00211	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RPTOR—glaucoma	3.26e-05	0.00203	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NCK2—glaucoma	3.16e-05	0.00197	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—VEGFA—glaucoma	3.14e-05	0.00196	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	3.13e-05	0.00195	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HDAC9—glaucoma	3.06e-05	0.00191	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—SMO—glaucoma	3.01e-05	0.00188	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—EDN1—glaucoma	2.94e-05	0.00184	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TXN—glaucoma	2.87e-05	0.00179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RPTOR—glaucoma	2.76e-05	0.00172	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—glaucoma	2.69e-05	0.00168	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HDAC9—glaucoma	2.68e-05	0.00168	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	2.68e-05	0.00167	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EDN1—glaucoma	2.67e-05	0.00167	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCK2—glaucoma	2.67e-05	0.00167	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—EDN1—glaucoma	2.58e-05	0.00161	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—C3—glaucoma	2.57e-05	0.00161	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	2.5e-05	0.00156	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMO—glaucoma	2.4e-05	0.0015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EDN1—glaucoma	2.34e-05	0.00146	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—C3—glaucoma	2.34e-05	0.00146	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HDAC9—glaucoma	2.27e-05	0.00142	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—C3—glaucoma	2.26e-05	0.00141	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTT1—glaucoma	2.22e-05	0.00139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NTRK2—glaucoma	2.19e-05	0.00137	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—EDN1—glaucoma	2.18e-05	0.00136	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMO—glaucoma	2.1e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—C3—glaucoma	2.05e-05	0.00128	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA1—glaucoma	2.04e-05	0.00127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EDN1—glaucoma	1.98e-05	0.00124	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CTSA—glaucoma	1.98e-05	0.00123	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	1.97e-05	0.00123	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NTRK2—glaucoma	1.92e-05	0.0012	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—C3—glaucoma	1.91e-05	0.00119	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGFR—glaucoma	1.88e-05	0.00117	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA2—glaucoma	1.87e-05	0.00116	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	1.86e-05	0.00116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NTRK1—glaucoma	1.79e-05	0.00111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMO—glaucoma	1.78e-05	0.00111	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1B1—glaucoma	1.77e-05	0.0011	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCA1—glaucoma	1.77e-05	0.0011	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—C3—glaucoma	1.73e-05	0.00108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGFR—glaucoma	1.65e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN2B—glaucoma	1.65e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK2—glaucoma	1.62e-05	0.00101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EDN1—glaucoma	1.58e-05	0.000986	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NTRK1—glaucoma	1.57e-05	0.000978	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.55e-05	0.000968	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGF—glaucoma	1.45e-05	0.000906	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN2B—glaucoma	1.44e-05	0.000901	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—glaucoma	1.42e-05	0.000883	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGFR—glaucoma	1.39e-05	0.00087	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—glaucoma	1.38e-05	0.000865	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—C3—glaucoma	1.38e-05	0.000861	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.33e-05	0.000829	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK1—glaucoma	1.32e-05	0.000826	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TXN—glaucoma	1.31e-05	0.00082	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—glaucoma	1.28e-05	0.000802	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGF—glaucoma	1.27e-05	0.000794	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—glaucoma	1.27e-05	0.000794	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—glaucoma	1.25e-05	0.000781	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—glaucoma	1.22e-05	0.000761	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FN1—glaucoma	1.21e-05	0.000756	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—C3—glaucoma	1.21e-05	0.000755	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BAD—glaucoma	1.2e-05	0.000747	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.17e-05	0.000731	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—glaucoma	1.17e-05	0.000731	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—glaucoma	1.16e-05	0.000727	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—glaucoma	1.15e-05	0.00072	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—glaucoma	1.13e-05	0.000703	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—glaucoma	1.12e-05	0.000697	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGF—glaucoma	1.08e-05	0.000671	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—glaucoma	1.06e-05	0.000663	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BAD—glaucoma	1.05e-05	0.000655	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—C3—glaucoma	1.02e-05	0.000638	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—glaucoma	1.02e-05	0.000636	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—glaucoma	9.62e-06	0.000601	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—glaucoma	9.52e-06	0.000594	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—glaucoma	9.43e-06	0.000589	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—glaucoma	8.98e-06	0.00056	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BAD—glaucoma	8.87e-06	0.000554	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—glaucoma	8.72e-06	0.000544	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—glaucoma	8.44e-06	0.000527	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—glaucoma	8.34e-06	0.00052	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCA1—glaucoma	8.12e-06	0.000507	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1B1—glaucoma	8.12e-06	0.000507	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—glaucoma	7.98e-06	0.000498	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—glaucoma	7.72e-06	0.000482	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—glaucoma	7.31e-06	0.000456	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—glaucoma	7.13e-06	0.000445	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—glaucoma	6.93e-06	0.000433	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—glaucoma	6.77e-06	0.000423	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—glaucoma	6.49e-06	0.000405	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—glaucoma	6.18e-06	0.000386	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—glaucoma	6.08e-06	0.000379	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—glaucoma	5.74e-06	0.000358	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—glaucoma	5.72e-06	0.000357	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—glaucoma	5.34e-06	0.000333	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—glaucoma	5.29e-06	0.00033	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—glaucoma	5.24e-06	0.000327	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—glaucoma	5.14e-06	0.000321	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—glaucoma	4.59e-06	0.000287	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—glaucoma	4e-06	0.00025	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—glaucoma	3.88e-06	0.000242	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—glaucoma	3.66e-06	0.000228	CbGpPWpGaD
